<DOC>
	<DOCNO>NCT00383812</DOCNO>
	<brief_summary>1 . Primary objective . To evaluate Effects intravitreal Bevacizumab polypoidal choroidal vasculopathy ( PCV ) 2 . Secondary objective 1 . To assess change visual acuity 2 . To assess change lesion characteristic PCV - size PCV - fluorescein leakage - foveal thickness 3 . To investigate safety intravitreal Bevacizumab patient PCV 4 . To assess effect intravitreal Bevacizumab recurrence rate incidence submacular hemorrhage patient PCV</brief_summary>
	<brief_title>Intravitreal Bevacizumab Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male female , CNV secondary PCV BCVA 20/40 20/320 ( Snellen equivalent ) Evidence presume recent disease progression ( blood , growth FA , recent VA loss ) Uncontrolled glaucoma ocular condition would prevent improvement visual acuity Media opacity study eye preclude clinical photographic evaluation Intraocular surgery &lt; 1 month day 0 Use heparin/warfarin within 1 month prior injection Known allergy hypersensitivity fluorescein , indocyanine green povidone iodine Contraindication pupil dilation either eye Any condition precludes patient â€™ ability comply study requirement include completion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Polypoidal choroidal vasculopathy</keyword>
	<keyword>Intravitreal Bevacizumab</keyword>
</DOC>